Pfizer will present 57 infectious disease abstracts at IDWeek 2026, including Phase 3 Lyme vaccine findings, new pediatric pneumococcal data and real-world RSV effectiveness studies. The programme highlights pipeline progress while leaving important regulatory and clinical questions unresolved.
Avenzo's partner VelaVigo will disclose early human safety and efficacy findings for the Nectin-4/TROP2 antibody-drug conjugate VBC103 at ESMO Asia 2026. The presentation could clarify the clinical potential of dual-antigen targeting, while a separate United States study advances in urothelial cancer.
GSK expands Chai Discovery AI collaboration after wet-lab success. See what the binding results establish and what remains unproven.
Vaxcyte’s VAX-31 met pivotal Phase 3 immune-response endpoints as the company prices $1 billion to fund trials and manufacturing scale-up.
Merck & Co.’s Keytruda plus Padcev has won a positive European regulatory opinion for perioperative treatment of resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, potentially expanding an already important oncology franchise into a broader earlier-stage population.
The U.S. Food and Drug Administration has approved Priovant Therapeutics’ LISRAYA, or brepocitinib, for adults with dermatomyositis, creating the first FDA-approved oral treatment for the rare systemic autoimmune disease. The decision converts positive Phase 3 VALOR data into Roivant Sciences’ first commercial opportunity for a drug that is also being developed across several other immune-mediated
TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.